natgillin/translations-raw huggingface dataset:
Tenofovir alafenamide fumarate is mainly eliminated following metabolism to tenofovir.
Alafenamidtenofovirat fumarat se pretežno izloča po presnovi v tenofovir.
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and prodrug of tenofovir (2’-deoxyadenosine monophosphate analogue).
Alafenamidtenofovirat je nukleotidni zaviralec reverzne transkriptaze (NtRTI - nucleotide reverse transcriptase inhibitor) in fosfonoamidatno predzdravilo tenofovirja (analog 2’-deoksiadenozin monofosfata).
Tenofovir alafenamide is a substrate of OATP in vitro.
Alafenamidtenofovirat je in vitro substrat OATP.
Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 in vitro.
Alafenamidtenofovirat je in vitro substrat OATP1B1 in OATP1B3.
Tenofovir alafenamide is a ‘prodrug’ of tenofovir, meaning that it is converted into the active substance tenofovir in the body.
Alafenamidtenofovirat je „predzdravilo“ tenofovirja, kar pomeni, da se v zdravilno učinkovino tenofovir pretvori v telesu.
Tenofovir alafenamide is active against HBV but its clinical efficacy against this virus is not yet fully established.
Alafenamidtenofovirat deluje proti virusu hepatitisa B (HBV), vendar njegova klinična učinkovitost proti temu virusu še ni povsem dokazana.
Tenofovir alafenamide is active against hepatitis B virus (HBV), but its clinical efficacy against this virus is under investigation and is not yet fully established.
Alafenamidtenofovirat deluje proti virusu hepatitisa B (HBV), vendar njegovo klinično učinkovitost proti temu virusu še vedno preiskujejo in še ni povsem dokazana.
Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir.
Alafenamidtenofovirat se pretežno izloča po presnovi v tenofovir.
Tenofovir alafenamide is minimally metabolised by CYP3A4.
Alafenamidtenofovirat se minimalno presnavlja s CYP3A4.
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP2D6 in vitro.
Alafenamidtenofovirat in vitro ni zaviralec CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ali CYP2D6.
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.
Alafenamidtenofovirat ni zaviralec CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ali CYP2D6.
Tenofovir alafenamide is not an inhibitor of CYP3A4 in vivo.
Alafenamidtenofovirat in vivo ni zaviralec CYP3A4.
Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 in vitro.
Alafenamidtenofovirat in vitro ni zaviralec humane urid uridindifosfat-glukuroniltransferaze (UGT- uridine diphosphate glucuronosyltransferase) 1A1.
Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 in vitro.
Alafenamidtenofovirat in vitro ni zaviralec humane uridin-difosfo-glukuronoziltransferaze (UGT, uridine diphosphate glucuronosyltransferase) 1A1.
Tenofovir alafenamide is not an inhibitor or inducer of CYP3A4 in vivo.
Alafenamidtenofovirat in vivo ni zaviralec ali induktor CYP3A4.
Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages.
Alafenamidtenofovirat prodira v celice in zaradi večje stabilnosti v plazmi in aktivacije v celici s hidrolizo s pomočjo katepsina A je alafenamidtenofovirat bolj učinkovit kot dizoproksiltenofovirat fumarat pri koncentriranju tenofovirja v mononuklearnih celicah v periferni krvi (peripheral blood mononuclear cells, PBMC) ali drugih ciljnih celicah HIV, vključno z limfociti in makrofagi.
Tenofovir alafenamide is rapidly absorbed following oral administration, with peak plasma concentrations occurring at 15-45 minutes post-dose.
Po peroralnem dajanju se alafenamidtenofovirat hitro absorbira in doseže največjo koncentracijo v plazmi v roku 15–45 minut po odmerku.
Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Alafenamidtenofovirat se prenaša s P-glikoproteinom (P-gp) in proteinom, odpornim na raka dojke (BCRP, Breast Cancer Resistance Protein).
Tenofovir alafenamide is transported by P-gp and BCRP.
Alafenamidtenofovirat se prenaša s P-gp in BCRP.
Tenofovir alafenamide is transported by P-gp and breast cancer resistance protein (BCRP).
Alafenamidtenofovirat se prenaša s P-glikoproteinom (P-gp) in proteinom odpornosti pri raku dojke (BCRP-Breast Cancer Resistance Protein).
Tenofovir Alafenamide: AUC: ↑
Alafenamidtenofovirat: AUC: ↑
Tenofovir alafenamide: AUC: ↑ 32%
alafenamidtenofovirat: AUC: ↑ 32
Tenofovir Alafenamide: AUC: ↓
Alafenamidtenofovirat: AUC: ↓
Tenofovir and emtricitabine are closely related types of antiviral agent called reverse transcriptase inhibitors.
Tenofovir in emtricitabin sta sorodni protivirusni učinkovini, ki spadate med zaviralce reverzne transkriptaze.
Tenofovir and emtricitabine are related antiviral agents called reverse transcriptase inhibitors.
Tenofovir in emtricitabin sta povezani protivirusni sredstvi, imenovani zaviralci reverzne transkriptaze.
Tenofovir and Nevirapine Teva can be co-administered without dose adjustments.
Tenofovir in zdravilo Nevirapin Teva se lahko uporablja sočasno brez prilagajanja odmerkov.
Tenofovir and tenofovir disoproxil fumarate are not metabolised by liver enzymes.
Jetrni encimi ne presnavljajo dizoproksiltenofovirijevega fumarata.
Tenofovir and Viramune can be co- administered without dose adjustments.
Tenofovir in zdravilo Viramune lahko dajemo sočasno brez prilagajanja odmerkov.
tenofovir AUC ↑ 5%
tenofovir AUC ↑ 5
tenofovir AUC  10 %
AUC tenofovirja  10
tenofovir C24hr  13 %
C24ur tenofovirja  13
tenofovir C24hr  13 %
tenofovir C24ur  13
tenofovir Cmax ↑ 32%
tenofovir Cmax ↑ 32
tenofovir Cmax ↓ 23 %
Cmax tenofovirja  23
Tenofovir concentrations not measured, no effect is expected
Koncentracij tenofovira niso merili, učinkov se ne pričakuje.
tenofovir concentrations.
koncentracije tenofovirja.
Tenofovir diphosphate is a weak inhibitor of cellular polymerases α, β, and γ.
Tenofovir difosfat je šibek zaviralec celičnih polimeraz α, β in γ.
Tenofovir disoproxil
dizoproksiltenofovirijeveg a fumarata)
Tenofovir disoproxil 245 mg (as fumarate)
Dizoproksiltenofo virat 245 mg (v obliki fumarata)
Tenofovir disoproxil 245 mg (as fumarate) (n = 1584)
Dizoproksiltenofovirat 245 mg (v obliki fumarata) (n = 1.584)
Tenofovir disoproxil 245 mg (as fumarate) n = 176
245 mg dizoproksil- tenofovirata (v obliki dizoproksiltenofovirije vega fumarata) n = 176
Tenofovir disoproxil 245 mg (as fumarate) n = 250c
245 mg dizoproksil- tenofovirata (v obliki dizoproksiltenofovirij evega fumarata)
Tenofovir disoproxil fumarate
dizoproksiltenofovirat fumarat
Tenofovir disoproxil fumarate
Dizoproksiltenofovirijev fumarat
Tenofovir disoproxil fumarate
rilpivirin
Tenofovir disoproxil fumarate
tenofovir dizoproksilfumarat
Tenofovir disoproxil fumarate
tenofovirdizoproksilat fumarat
Tenofovir disoproxil fumarate (300 mg once daily)
dizoproksiltenofovirijev fumarat (300 mg enkrat dnevno)
Tenofovir disoproxil fumarate (n=45)
dizoproksiltenofovirijev fumarat (n = 45)
Tenofovir disoproxil fumarate 300 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Dizoproksiltenofovirat fumarat 300 mg enkrat na dan (atazanavir 300 mg enkrat na dan z ritonavirjem 100 mg enkrat na dan)
Tenofovir disoproxil fumarate at a concentration of 100 µmol/l had no effect on any of the CYP450 isoforms, except CYP1A1/2, where a small (6%) but statistically significant reduction in metabolism of CYP1A1/2 substrate was observed.
Dizoproksiltenofovirijev fumarat ni imel pri koncentraciji 100 µmol/l nobenega vpliva na katero koli obliko CYP450 izoformov, izjema je CYP1A1/2, kjer so opazili majhno (6%) toda statistično pomembno zmanjšanje presnove substrata za CYP1A1/2.
Tenofovir disoproxil fumarate AUC
Dizoproksiltenofovirat fumarat AUC
Tenofovir disoproxil fumarate Cmax
Dizoproksiltenofovirat fumarat Cmax
Tenofovir disoproxil fumarate Cmin
Dizoproksiltenofovirat fumarat Cmin
Tenofovir disoproxil fumarate had no effect on any of the CYP450 isoforms, except CYP1A1/2, where a small (6%) but statistically significant reduction in metabolism of a CYP1A1/2 substrate was observed.
Dizoproksiltenofovirijev fumarat ni imel učinka na nobeno od izooblik CYP450, razen na CYP1A1/2, kjer so opazili majhno (6 %), a statistično značilno zmanjšanje presnove substrata CYP1A1/2.
Tenofovir disoproxil fumarate has not been clinically evaluated in patients receiving medicinal products which are secreted by the same renal pathway, including the transport proteins human organic anion transporter (hOAT) 1 and 3 or MRP 4 (e.g. cidofovir, a known nephrotoxic medicinal product).
Uporaba dizoproksiltenofovirijevega fumarata klinično ni bila ovrednotena pri bolnikih, ki so prejemali zdravila, ki se izločajo po isti ledvični metabolni poti, vključno s transportnimi beljakovinami hOAT (human organic anion transporter) 1 in 3 ali MRP 4 (npr. cidofovir, znano nefrotoksičeno zdravilo).
Tenofovir disoproxil fumarate has not been studied in patients over the age of 65.
Dizoproksiltenofovirijevega fumarata niso proučevali pri bolnikih starejših od 65 let.
Tenofovir disoproxil fumarate has not been studied in patients over the age of 65.
Dizoproksiltenofovirijevega fumarata niso proučevali pri bolnikih, starejših od 65 let.
Tenofovir disoproxil fumarate is a water soluble ester prodrug which is rapidly converted in vivo to tenofovir and formaldehyde.
Dizoproksiltenofovirijev fumarat je vodotopen ester, predzdravilo, ki se in vivo hitro pretvori v tenofovir in formaldehid.
Tenofovir disoproxil fumarate is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate.
Dizoproksiltenofovirijev fumarat se in vivo pretvori v tenofovir, nukleozidni monofosfatni (nukleotidni) analog adenozin monofosfata.
Tenofovir disoproxil fumarate is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate.
Dizoproksiltenofovirijev fumarat se in vivo pretvori v tenofovir, nukleozidni monofosfatni (nukleotidni) analog adenozinmonofosfata.
Tenofovir disoproxil fumarate is the fumarate salt of the prodrug tenofovir disoproxil.
Dizoproksiltenofovirijev fumarat je fumaratna sol predzdravila dizoproksiltenofovirata.
Tenofovir disoproxil fumarate must be taken with food, as food enhances the bioavailability of tenofovir (see section 5.2).
Dizoproksiltenofovirijev fumarat se mora jemati s hrano, kajti hrana poviša biološko razpoložljivost tenofovirja (glejte poglavje 5.2).
tenofovir disoproxil fumarate or any medicine containing tenofovir disoproxil fumarate, used to treat HIV infection;
dizoproksiltenofovirat fumarat ali katero koli zdravilo, ki vsebuje dizoproksiltenofovirat fumarat, ki se uporablja za zdravljenje okužbe s HIV,
tenofovir disoproxil fumarate or any medicine containing tenofovir disoproxil fumarate, used to treat HIV infection;
dizoproksiltenofovirijev fumarat ali katero koli zdravilo, ki vsebuje dizoproksiltenofovirijev fumarat, ki se uporablja za zdravljenje okužbe z virusom HIV;
tenofovir disoproxil fumarate plus emtricitabine zidovudine plus lamivudine abacavir plus lamivudine
tenofovir dizoproksil fumarat in emtricitabin zidovudin in lamivudin abakavir in lamivudin
Tenofovir disoproxil fumarate should be avoided in antiretroviral-experienced patients with strains harbouring the K65R mutation (see section 4.4).
Uporabi dizoproksiltenofovirijevega fumarata se je potrebno izogniti pri bolnikih s sevom nosilcem K65R mutacije, ki so že bili zdravljeni s protiretrovirusnimi zdravili (glejte poglavje 4.4).
Tenofovir disoproxil fumarate should be avoided in patients with HIV-1 harbouring the K65R mutation.
Uporabi dizoproksiltenofovirijev fumarata se je treba izogniti pri bolnikih, okuženih z virusom HIV-1, ki ima mutacijo K65R.
Tenofovir disoproxil fumarate should be avoided in patients with HIV-1 harbouring the K65R mutation.
Uporabi dizoproksiltenofovirijevega fumarata se je potrebno izogniti pri bolnikih s HIV-1, nosilci mutacije K65R.
Tenofovir disoproxil fumarate should be avoided in patients with HIV-1 harbouring the K65R substitution.
Uporabi dizoproksiltenofovirijevega fumarata se je potrebno izogniti pri bolnikih s HIV-1, nosilci substitucije K65R.
Tenofovir disoproxil fumarate should not be administered concurrently with adefovir dipivoxil (see section 4.4).
Dizoproksiltenofovirijevega fumarata se ne sme uporabljati skupaj z dipivoksiladefoviratom (glejte poglavje 4.4).
Tenofovir disoproxil fumarate should not be initiated in paediatric patients with renal impairment and should be discontinued in paediatric patients who develop renal impairment during tenofovir disoproxil fumarate therapy.
Zdravljenja z dizoproksiltenofovirijevim fumaratom se ne sme začeti pri pediatričnih bolnikih z ledvično okvaro in ga je treba prekiniti pri pediatričnih bolnikih, pri katerih se po začetku zdravljenja z dizoproksiltenofovirijevim fumaratom razvije ledvična okvara.
Tenofovir disoproxil fumarate*#
tenofovir dizoproksil fumarat*#
Tenofovir disoproxil fumarate: AUC: ↔
dizoproksiltenofovirijev fumarat: AUC: ↔
Tenofovir disoproxil fumarate: Non-clinical safety pharmacology studies on tenofovir disoproxil fumarate reveal no special hazard for humans.
Dizoproksiltenofovirijev fumarat: Predklinične študije farmakološke varnosti dizoproksiltenofovirijevega fumarata ne kažejo posebnega tveganja za človeka.
Tenofovir disoproxil fumarate: Non-clinical safety pharmacology studies on tenofovir disoproxil fumarate reveal no special hazard for humans.
Dizoproksiltenofovirijev fumarat: Predklinične študije farmakološke varnosti za dizoproksiltenofovirijev fumarat ne kažejo posebnega tveganja za človeka.
Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate (nucleotide) analogue.
Dizoproksiltenofovirat se absorbira in pretvori v zdravilno učinkovino tenofovir, ki je analog nukleozid (nukleotid) monofosfata.
Tenofovir displayed antiviral activity in cell culture against HIV-1 subtype A, B, C, D, E, F, G, and O (EC50 values ranged from 0.5 to 2.2 µM) and strain specific activity against HIV-2 (EC50 values ranged from 1.6 µM to 5.5 µM).
Tenofovir je pokazal protiretrovirusno aktivnost v celični kulturi proti podtipom A, B, C, D, E, F, G in O virusa HIV-1 (vrednosti EC50 so bile v razponu od 0,5 do 2,2 µM) in aktivnost, specifično za sev, proti virusu HIV-2 (vrednost EC50 so bile v razponu od 1,6 µM do 5,5 µM).
Tenofovir exposure achieved in 8 paediatric patients (12 to < 18 years of age) receiving oral daily doses of tenofovir disoproxil fumarate 300 mg (tablet) was similar to exposures achieved in adults receiving once-daily doses of 300 mg.
Izpostavljenost tenofovirju pri 8 pediatričnih bolnikih (12 do < 18 let starosti), ki so peroralno dobivali dnevne odmerke dizoproksiltenofovirijevega fumarata 300 mg (tableta) je bila podobna izpostavljenosti, doseženi pri odraslih, ki so enkrat dnevno dobivali odmerek 300 mg.
Tenofovir exposure achieved in adolescent patients receiving oral daily doses of tenofovir disoproxil 245 mg (as fumarate) was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil 245 mg (as fumarate).
Izpostavljenost tenofovirju, dosežena pri mladostnikih, ki so peroralno prejemali dnevni odmerek 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata), je bila podobna kot izpostavljenost, dosežena pri odraslih, ki so prejemali enkratni dnevni odmerek 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata).
Tenofovir exposure achieved in these paediatric patients receiving oral daily doses of tenofovir disoproxil 245 mg (as fumarate) or 6.5 mg/kg body weight tenofovir disoproxil (as fumarate) up to a maximum dose of 245 mg was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil 245 mg (as fumarate).
Izpostavljenost tenofovirju, dosežena pri pediatričnih bolnikih, ki so peroralno prejemali dnevne odmerke dizoproksiltenofovirata 245 mg (v obliki fumarata) ali 6,5 mg/kg telesne mase dizoproksiltenofovirata (v obliki fumarata) do največjega odmerka 245 mg, je bila podobna izpostavljenosti pri odraslih, ki so prejemali odmerke dizoproksiltenofovirata 245 mg (v obliki fumarata) enkrat dnevno.
Tenofovir exposure achieved in these paediatric patients receiving oral daily doses of tenofovir disoproxil 245 mg (as fumarate) or 6.5 mg/kg body weight tenofovir disoproxil (as fumarate) up to a maximum dose of 245 mg was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil 245 mg (as fumarate).
Izpostavljenost tenofovirju, dosežena pri teh pediatričnih bolnikih, ki so peroralno prejemali dnevni odmerek 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) ali 6,5 mg/kg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) na telesno maso do največjega odmerka 245 mg, je bila podobna kot izpostavljenost, dosežena pri odraslih, ki so prejemali enkratni dnevni odmerek 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata).
Tenofovir exposure achieved in these paediatric patients receiving oral daily doses of tenofovir disoproxil 245 mg or 6.5 mg/kg body weight tenofovir disoproxil up to a maximum dose of 245 mg was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil 245 mg.
Izpostavljenost tenofovirju, dosežena pri pediatričnih bolnikih, ki so peroralno prejemali dnevne odmerke dizoproksiltenofovirata 245 mg ali 6,5 mg/kg telesne mase dizoproksiltenofovirata do največjega odmerka 245 mg, je bila podobna izpostavljenosti pri odraslih, ki so prejemali odmerke dizoproksiltenofovirata 245 mg enkrat dnevno.
Tenofovir has activity against HIV-1, HIV-2, and hepatitis B virus.
Tenofovir je aktiven proti HIV-1, HIV-2 in virusu hepatitisa B.
Tenofovir is a nucleotide reverse transcriptase inhibitor, generally known as an NRTI and works by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself.
Tenofovir je nukleotidni zaviralec reverzne transkriptaze, ki je splošno znan pod imenom NRTI (nucleotide reverse transcriptase inhibitors), in deluje tako, da vpliva na normalno delovanje encima (reverzne transkriptaze), ki je bistven za pomnoževanje virusa.
Tenofovir is eliminated from the body by the kidneys by both glomerular filtration and active tubular secretion.
Tenofovir se iz telesa izloča preko ledvic tako z glomerularno filtracijo kot z aktivno tubularno sekrecijo.
Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system with approximately 70 – 80% of the dose excreted unchanged in urine following intravenous administration.
Tenofovir se primarno izloča preko ledvic tako s filtracijo kot z aktivnim tubularnim transportnim sistemom, pri čemer se po intravenskem vnosu približno 70-80% odmerka izloči nespremenjenega z urinom.
Tenofovir may decrease the AUC
Tenofovir lahko zmanjša vrednosti
Tenofovir pharmacokinetics were not substantially altered in subjects with hepatic impairment suggesting that no dose adjustment of tenofovir disoproxil fumarate is required in these subjects.
Farmakokinetika tenofovirja se pri osebah z jetrno okvaro ni bistveno spremenila, kar nakazuje, da pri teh osebah ni treba prilagoditi odmerjanja dizoproksiltenofovirijevega fumarata.
tenofovir plasma concentrations.
tenofovirja v plazmi.
Tenofovir, 300 mg QD
tenofovir,
Tenofovir, 300 mg QD
Tenofovir, 300 mg
tenofovir-associated adverse
neželene učinke tenofovirja,
tenofovir.
prilagoditi.
Tenofovir/emtricitabine
tenofovir/emtricitabi n
Tenofovir:
Cmin: n/i tenofovir:
Tenofovir:
emtricitabin:
Tenofovir:
metadon:
Tenofovir:
očasni uporabi z
Tenofovir:
ribavirin:
Tenofovir:
rilpivirin:
Tenofovir: AUC: ↑ 32%
tenofovir: AUC: ↑ 32
Tenofovir: AUC: ↔
Cmin: ni bilo izračunano tenofovir: AUC: ↔
Tenosynovitis
tenosinovitis
tenosynovitis (tendonitis, synovitis and tendon pain)
tendosinovitis (tendinitis, sinovitis in bolečina v kitah)
tenosynovitiss
tendosinovitiss
Tension headache*
tenzijski glavobol
TEPADINA 100 mg powder for concentrate for solution for infusion thiotepa
TEPADINA 100 mg prašek za koncentrat za raztopino za infundiranje tiotepa
Tepadina can be used for transplantation of cells from a donor and for transplantation of cells derived from the patient’s own body.
Zdravilo Tepadina se lahko uporablja za presaditev darovalčevih celic in za presaditev celic, ki izvirajo iz telesa bolnika samega.
TEPADINA contains the active substance thiotepa, which belongs to a group of medicines called alkylating agents.
Zdravilo TEPADINA vsebuje zdravilno učinkovino tiotepa, ki spada v skupino zdravil, imenovanih alkilirajoče učinkovine.
TEPADINA does not contain any excipients.
Zdravilo TEPADINA ne vsebuje pomožnih snovi.
TEPADINA does not contain any other ingredients.
Zdravilo TEPADINA ne vsebuje pomožnih snovi.
TEPADINA is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Zdravilo TEPADINA se uporablja v kombinaciji z drugimi kemoterapevtiki: kot pripravljalno zdravljenje (kondicioniranje) z obsevanjem celega telesa ali brez obsevanja, pred alogensko ali avtologno presaditvijo krvotvornih matičnih celic (PKMC) pri hematoloških boleznih pri odraslih in pediatričnih bolnikih; ko je kemoterapija z visokimi odmerki podprta s PKMC primerna za zdravljenje čvrstih tumorjev pri odraslih in pediatričnih bolnikih.
TEPADINA is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Zdravilo TEPADINA se uporablja v kombinaciji z drugimi kemoterapevtiki: kot pripravljalno zdravljenje (kondicioniranje) z obsevanjem celega telesa ali brez obsevanja, pred alogensko ali avtologno presaditvijo krvotvornih matičnih celic (PKMC) pri hematoloških boleznih pri odraslih in pediatričnih bolnikih; ko je kemoterapija z visokimi odmerki s podporo PKMC primerna za zdravljenje čvrstih tumorjev pri odraslih in pediatričnih bolnikih.
Tepadina is used with other medicines before transplantation to destroy the abnormal cells and the patient’s existing blood-making cells.
Zdravilo Tepadina se uporablja z drugimi zdravili pred presaditvijo za uničenje nenormalnih celic in bolnikovih obstoječih krvotvornih celic.
TEPADINA must be reconstituted with 1.5 ml of sterile water for injection.
Zdravilo TEPADINA se rekonstituira z 1,5 ml sterilne vode za injekcije.
TEPADINA must be reconstituted with 1.5 ml of sterile water for injections.
Zdravilo TEPADINA se rekonstituira z 1,5 ml sterilne vode za injekcije
TEPADINA must be reconstituted with 10 ml of sterile water for injection.
Zdravilo TEPADINA se rekonstituira z 10 ml sterilne vode za injekcije.
TEPADINA must be reconstituted with 10 ml of sterile water for injections.
Zdravilo TEPADINA se rekonstituira z 10 ml sterilne vode za injekcije.
TEPADINA posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease.
O odmerjanju zdravila TEPADINA se določi pri odraslih in pediatričnih bolnikih glede na vrsto PKMC (avtologna ali alogenska) in bolezen.
TEPADINA posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease.
Odmerjanje zdravila TEPADINA se določi pri odraslih in pediatričnih bolnikih glede na vrsto PKMC (avtologna ali alogenska) in bolezen.